Who has been buying GFC Life Science stock?

2 distinct insiders have filed 12 disclosed insider purchases in GFC Life Science (388610), most recently on 2026-07-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does GFC Life Science have?

GFC Life Science has 12 buy-side and 0 sell-side disclosures on record, covering ₩152M ($105K) in total reported value, spanning 2025-11-06 to 2026-07-15.

Where does StockDrifts get GFC Life Science insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

GFC Life Science 388610

Company

지에프씨생명과학GFC Life Science

Insiders

Buys

Total Value

₩152M ($105K)

Avg Return

-0.91%

Last Filing

2026-07-15

GFC Life Science (388610) has 12 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩152M ($105K) in reported transaction value. The earliest filing StockDrifts holds for GFC Life Science is dated 2025-11-06; the most recent is 2026-07-15. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -0.91%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-07	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	94	₩6,110	+4.9%	₩565K ($392)
2026-08-06	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	229	₩6,020	+1.5%	₩1M ($938)
2026-08-06	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	240	₩6,020	+6.5%	₩1M ($1K)
2026-08-05	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.4K	₩5,980	+2.2%	₩8M ($6K)
2026-08-05	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	163	₩5,980	+7.2%	₩982K ($682)
2026-08-04	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	553	₩5,900	+3.6%	₩3M ($2K)
2026-08-03	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	2.3K	₩5,650	+8.1%	₩12M ($8K)
2026-07-31	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	2.8K	₩5,410	+0.0%	₩14M ($10K)
2026-07-23	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	836	₩6,000	-2.0%	₩5M ($3K)
2026-07-22	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.6K	₩5,800	+1.4%	₩10M ($7K)
2026-07-21	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	999	₩5,800	+1.4%	₩6M ($4K)
2026-07-20	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	370	₩5,800	+1.4%	₩2M ($2K)
2026-07-16	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	4.7K	₩6,040	-2.6%	₩26M ($18K)
2026-07-15	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	4.4K	₩5,900	+2.4%	₩24M ($17K)
2026-07-14	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.0K	₩5,620	+7.5%	₩5M ($4K)
2026-07-13	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	3.7K	₩5,570	+8.4%	₩17M ($12K)
2026-05-18	BUY	주식매수선택권	이동환 Donghwan Lee	Managing Director	21.7K	₩8,300	-10.4%	₩180M ($125K)
2026-04-10	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	417	₩9,390	+7.6%	₩4M ($3K)
2026-04-09	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.9K	₩9,240	+9.3%	₩17M ($12K)
2026-04-08	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	3.3K	₩9,530	+6.0%	₩32M ($22K)
2026-04-07	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	961	₩9,490	+6.4%	₩9M ($6K)
2026-04-06	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.2K	₩9,500	+6.3%	₩11M ($8K)
2026-04-01	BUY	Market Buy	민진우 Jinwoo Min	Internal director	100	₩9,490	+6.4%	₩949K ($659)
2026-03-26	BUY	신규선임	민진우 Jinwoo Min	Internal director	20.8K	₩10,070	+1.2%	₩210M ($146K)
2025-11-10	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	23	₩15,060	-24.2%	₩346K ($241)
2025-11-09	SELL	특별관계해소	표형배 Hyeongbae Pyo	Clinical Division Representative	-7.5K	₩15,060	+24.2%	₩113M ($78K)
2025-11-07	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	739	₩14,760	-22.7%	₩11M ($8K)
2025-11-06	BUY	Market Buy	강희철 Kang Hee-cheol	CEO	1.3K	₩15,080	-24.3%	₩20M ($14K)

Frequently asked questions

Who has been buying GFC Life Science stock?: 2 distinct insiders have filed 12 disclosed insider purchases in GFC Life Science (388610), most recently on 2026-07-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does GFC Life Science have?: GFC Life Science has 12 buy-side and 0 sell-side disclosures on record, covering ₩152M ($105K) in total reported value, spanning 2025-11-06 to 2026-07-15.
Where does StockDrifts get GFC Life Science insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for GFC Life Science. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.